Blog

Lauren Brown: Another insightful article out of the AURORA collaboration

Photo taken from www.clinical-lung-cancer.com

May 10, 2024, 14:58

Lauren Brown: Another insightful article out of the AURORA collaboration

Lauren Brown, PhD Candidate at Westmead Institute for Medical Research, University of Sydney & Medical Oncology Fellow at Westmead and Blacktown Hospitals, made the following post on X:

“Another insightful article out of the AURORA collaboration. Patients with KRAS, or PDL1 ≥50% are more likely to complete 24-months of pembro for NSCLC. Patients with oligoprogression in the brain treated with RT can still have enduring responses.”

Read the article.
Source: Lauren Brown/X

AURORA collaboration Blacktown Hospital brain metastases cancer cancer treatment KRAS mutation Lauren Brown Medical Oncology Fellow Medical Research NSCLC oligoprogression OncoDaily Oncology PD-L1 pembrolizumab PhD Candidate radiotherapy Research University of Sydney Westmead Hospital Westmead Institute for Medical Research

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer